Survival and prognostic factors of early‐stage non‐small cell lung cancer in Central and Eastern Europe: A prospective cohort study

Author:

Sheikh Mahdi1ORCID,Virani Shama1ORCID,Robbins Hilary A.1ORCID,Foretova Lenka2ORCID,Holcatova Ivana34,Janout Vladimir5,Lissowska Jolanta6ORCID,Navratilova Marie2,Mukeriya Anush7,Ognjanovic Miodrag8,Swiatkowska Beata9,Zaridze David7ORCID,Brennan Paul1ORCID

Affiliation:

1. Genomic Epidemiology Branch International Agency for Research on Cancer (IARC/WHO) Lyon France

2. Department of Cancer Epidemiology & Genetics Masaryk Memorial Cancer Institute Brno Czech Republic

3. Department of Public Health and Preventive Medicine, Second Faculty of Medicine Charles University Prague Czech Republic

4. Department of Oncology 2nd Medical Faculty & University Hospital Motol Prague Czech Republic

5. Faculty of Medicine Palacky University Olomouc Czech Republic

6. Department of Cancer Epidemiology and Prevention M. Sklodowska‐Curie National Research Institute of Oncology Warsaw Poland

7. Department of Clinical Epidemiology N.N. Blokhin National Medical Research Centre of Oncology Moscow Russia

8. International Organization for Cancer Prevention and Research Belgrade Serbia

9. Department of Environmental Epidemiology Nofer Institute of Occupational Medicine Poland

Abstract

AbstractBackgroundAlthough early diagnosis and surgical resection of the tumor have been shown to be the most important predictors of lung cancer survival, long‐term survival for surgically‐resected early‐stage lung cancer remains poor.AimsIn this prospective study we aimed to investigate the survival and prognostic factors of surgically‐resected early‐stage non‐small cell lung cancer (NSCLC) in Central and Eastern Europe.MethodsWe recruited 2052 patients with stage I‐IIIA NSCLC from 9 centers in Russia, Poland, Serbia, Czech Republic, and Romania, between 2007–2016 and followed them annually through 2020.ResultsDuring follow‐up, there were 1121 deaths (including 730 cancer‐specific deaths). Median survival time was 4.9 years, and the 5‐year overall survival was 49.5%. In the multivariable model, mortality was increased among older individuals (HR for each 10‐year increase: 1.31 [95% CI: 1.21–1.42]), males (HR:1.24 [1.04–1.49]), participants with significant weight loss (HR:1.25 [1.03–1.52]), current smokers (HR:1.30 [1.04–1.62]), alcohol drinkers (HR:1.22 [1.03–1.44]), and those with higher stage tumors (HR stage IIIA vs. I: 5.54 [4.10 – 7.48]). However, education, chronic obstructive pulmonary diseases (COPD), and tumor histology were not associated with risk of death. All baseline indicators of smoking and alcohol drinking showed a dose‐dependent association with the risk of cancer‐specific mortality. This included pack‐years of cigarettes smoked (p‐trend = 0.04), quantity of smoking (p‐trend = 0.008), years of smoking (p‐trend = 0.010), gram‐days of alcohol drank (p‐trend = 0.002), frequency of drinking (p‐trend = 0.006), and years of drinking (p‐trend = 0.016).ConclusionThis study shows that the 5‐year survival rate of surgically‐resected stage I‐IIIA NSCLC is still around 50% in Central and Eastern Europe. In addition to non‐modifiable prognostic factors, lifetime patterns of smoking and alcohol drinking affected the risk of death and disease progression in a dose‐dependent manner in this population.

Funder

Centre International de Recherche sur le Cancer

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Reference49 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

3. World Health Organization.World Cancer Report: Cancer Research for Cancer Prevention.2020Accessed April 21 2020.https://publications.iarc.fr/Non‐Series‐Publications/World‐Cancer‐Reports/World‐Cancer‐Report‐Cancer‐Research‐For‐Cancer‐Prevention‐2020

4. Lung Cancer Survival Statistics [Internet].Cancer Research UK.2015Accessed April 21 2020.https://www.cancerresearchuk.org/health‐professional/cancer‐statistics/statistics‐by‐cancer‐type/lung‐cancer/survival

5. Survival patterns in lung and pleural cancer in Europe 1999–2007: Results from the EUROCARE-5 study

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3